X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Applications - 12/Aug 01:08

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye...

Articles similaires

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

drugs.com - 14/Sep 05:09

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...

Sorry! Image not available at this time

Relief Therapeutics presents PKU GOLIKE study results at SSIEM 2024

pharmabiz.com - 03/Sep 00:00

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...

Sorry! Image not available at this time

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

menafocus.qa - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

pressarabia.qa - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Les derniers communiqués